These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


122 related items for PubMed ID: 3825747

  • 21. Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis.
    Pasternak RD, Wadopian NS, Wright RN, Siminoff P, Gylys JA, Buyniski JP.
    Agents Actions; 1987 Aug; 21(3-4):241-3. PubMed ID: 3500589
    [Abstract] [Full Text] [Related]

  • 22. The effect of OM-89 (Subreum) on the murine model of systemic lupus erythematosus MRL-lpr/lpr.
    Dhaher YY, Khamashta MA, Hartley B, Taub N, Farine JC, Hughes GR.
    Lupus; 1997 Aug; 6(5):436-40. PubMed ID: 9229361
    [Abstract] [Full Text] [Related]

  • 23. Immunosupressive or anti-inflammatory?
    Br Med J; 1967 Mar 18; 1(5541):650-1. PubMed ID: 6019660
    [No Abstract] [Full Text] [Related]

  • 24. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study.
    Remer CF, Weisman MH, Wallace DJ.
    Lupus; 2001 Mar 18; 10(7):480-3. PubMed ID: 11480845
    [Abstract] [Full Text] [Related]

  • 25. Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).
    Katzav A, Kloog Y, Korczyn AD, Niv H, Karussis DM, Wang N, Rabinowitz R, Blank M, Shoenfeld Y, Chapman J.
    Clin Exp Immunol; 2001 Dec 18; 126(3):570-7. PubMed ID: 11737078
    [Abstract] [Full Text] [Related]

  • 26. Effect of cyclophosphamide on leukocytic infiltration in the brain of MRL/lpr mice.
    Farrell M, Sakić B, Szechtman H, Denburg JA.
    Lupus; 1997 Dec 18; 6(3):268-74. PubMed ID: 9104735
    [Abstract] [Full Text] [Related]

  • 27. 6-Sulfanilamidoindazole arthritis in rats: influence of the new anti-inflammatory agent CGP 28237 and of the immunomodulating compound HWA 486 on degree of arthritis and on acute phase reaction.
    Hirschelmann R, Schade R.
    Pharmazie; 1988 Jan 18; 43(1):54. PubMed ID: 3131786
    [No Abstract] [Full Text] [Related]

  • 28. Behaviour of MRL mice: an animal model of disturbed behaviour in systemic autoimmune disease.
    Szechtman H, Sakić B, Denburg JA.
    Lupus; 1997 Jan 18; 6(3):223-9. PubMed ID: 9104727
    [Abstract] [Full Text] [Related]

  • 29. Therapeutic potential of IL-27 in systemic lupus erythematosus.
    Pan HF, Tao JH, Ye DQ.
    Expert Opin Ther Targets; 2010 May 18; 14(5):479-84. PubMed ID: 20350048
    [Abstract] [Full Text] [Related]

  • 30. Prolactin: a stimulator of disease activity in systemic lupus erythematosus.
    Walker SE, Allen SH, Hoffman RW, McMurray RW.
    Lupus; 1995 Feb 18; 4(1):3-9. PubMed ID: 7767336
    [No Abstract] [Full Text] [Related]

  • 31. Modulation of toll-like receptor function has therapeutic potential in autoimmune disease.
    Clanchy FI, Sacre SM.
    Expert Opin Biol Ther; 2010 Dec 18; 10(12):1703-16. PubMed ID: 21039312
    [Abstract] [Full Text] [Related]

  • 32. Lack of relationship between serum gp70 levels and the severity of systemic lupus erythematosus in MRL/l mice.
    Andrews J, Hang L, Theofilopoulos AN, Dixon FJ.
    J Exp Med; 1986 Feb 01; 163(2):458-62. PubMed ID: 3944541
    [Abstract] [Full Text] [Related]

  • 33. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.
    Cai Z, Wong CK, Dong J, Chu M, Jiao D, Kam NW, Lam CW, Tam LS.
    Clin Exp Immunol; 2015 Aug 01; 181(2):253-66. PubMed ID: 25845911
    [Abstract] [Full Text] [Related]

  • 34. Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
    Fragoso YD, Brooks JB.
    Expert Rev Clin Pharmacol; 2015 May 01; 8(3):315-20. PubMed ID: 25712857
    [Abstract] [Full Text] [Related]

  • 35. Leflunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis.
    Bartlett RR, Brendel S, Zielinski T, Schorlemmer HU.
    Transplant Proc; 1996 Dec 01; 28(6):3074-8. PubMed ID: 8962190
    [No Abstract] [Full Text] [Related]

  • 36. [Multidrug resistance: a century after "606"].
    Llorente L, Richaud-Patin Y, Jakez-Ocampo J.
    Rev Invest Clin; 2001 Dec 01; 53(5):444-51. PubMed ID: 11795110
    [No Abstract] [Full Text] [Related]

  • 37. Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL/MpSlac-lpr mice.
    Yan SX, Deng XM, Wang QT, Sun XJ, Wei W.
    Acta Pharmacol Sin; 2015 Nov 01; 36(11):1367-76. PubMed ID: 26456588
    [Abstract] [Full Text] [Related]

  • 38. Curcumin attenuates murine lupus via inhibiting NLRP3 inflammasome.
    Zhao J, Wang J, Zhou M, Li M, Li M, Tan H.
    Int Immunopharmacol; 2019 Apr 01; 69():213-216. PubMed ID: 30738291
    [Abstract] [Full Text] [Related]

  • 39. [Glomerulonephritis in systemic lupus erythematosus].
    Belovezhdov N.
    Vutr Boles; 1984 Apr 01; 23(1):1-9. PubMed ID: 6203232
    [No Abstract] [Full Text] [Related]

  • 40. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
    Zhou L, Sun L, Wu H, Zhang L, Chen M, Liu J, Zhong R.
    Eur J Pharmacol; 2013 Sep 05; 715(1-3):230-7. PubMed ID: 23712004
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 7.